These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 2418656)
21. Highly efficient synthesis of carbacyclins and isocarbacyclin. Shibasaki M; Sodeoka M; Ogawa Y; Mase T Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():283-5. PubMed ID: 2936106 [No Abstract] [Full Text] [Related]
22. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro. Maurin N Arzneimittelforschung; 1986 Aug; 36(8):1180-3. PubMed ID: 3096342 [TBL] [Abstract][Full Text] [Related]
23. Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbacyclin derivative (ZK 36 375). Schrör K; Darius H; Ohlendorf R; Matzky R; Klaus W J Cardiovasc Pharmacol; 1982; 4(4):554-61. PubMed ID: 6181328 [TBL] [Abstract][Full Text] [Related]
24. Syntheses of 13-oxa- and 13-thiaprostacyclins: biologically potent analogs of prostacyclin. Novák L; Aszódi J; Stadler I; Körmöczy P; Simonidesz V; Szántay C Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():275-80. PubMed ID: 6221537 [No Abstract] [Full Text] [Related]
25. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. Mackie IJ; Jones R; Machin SJ J Clin Pathol; 1984 Aug; 37(8):874-8. PubMed ID: 6206096 [TBL] [Abstract][Full Text] [Related]
26. Platelet inhibitory activity of prostacyclin in the presence of erythrocytes as studied with the impedance aggregometer. Gresele P; Deckmyn H; Arnout J; Vermylen J Br J Haematol; 1984 May; 57(1):171-3. PubMed ID: 6372851 [No Abstract] [Full Text] [Related]
27. Hemodialysis with the stable prostacyclin analogue CG 4203. Maurin N Prog Clin Biol Res; 1987; 242():479-84. PubMed ID: 3313422 [No Abstract] [Full Text] [Related]
28. Changes in some aspects of platelet function with improvement of glycaemic control over 6 months. Collier A; Tymkewycz PM; Matthews DM; Jones RL; Clarke BF Diabetes Res; 1987 Jun; 5(2):79-82. PubMed ID: 2443296 [TBL] [Abstract][Full Text] [Related]
29. Synergistic actions of prostacyclin and an isoquinoline derivative (CH-102) on ADP-induced aggregation of dog platelets in vitro. Pataricza J; Bor P; Szekeres L Biomed Biochim Acta; 1984; 43(12):1365-9. PubMed ID: 6398698 [TBL] [Abstract][Full Text] [Related]
30. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Sim AK; McCraw AP; Cleland ME; Nishio S; Umetsu T Arzneimittelforschung; 1985; 35(12):1816-8. PubMed ID: 3913423 [TBL] [Abstract][Full Text] [Related]
31. [Effect of heparin and prostacyclin on blood platelet activity]. Kisiel S; Myśliwiec M; Jakubowska I; Rydzewski A Pol Tyg Lek; 1983 Jun; 38(24):717-20. PubMed ID: 6359097 [No Abstract] [Full Text] [Related]
32. Preservation of platelet function in cryopreserved platelet concentrates with prostacyclin. Johnson EJ; Mackie IJ; Machin SJ; Brozović B Clin Lab Haematol; 1984; 6(2):141-4. PubMed ID: 6207975 [TBL] [Abstract][Full Text] [Related]
33. Convenient synthesis of CS-570, a chemically stable prostacyclin analogue. Kojima K; Amemiya S; Sakai K; Kobayashi S Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():287-9. PubMed ID: 2936107 [No Abstract] [Full Text] [Related]
34. Syntheses and biological activities of some prostacyclin analogs. Ohuchida S; Hashimoto S; Wakatsuka H; Arai Y; Hayashi M Adv Prostaglandin Thromboxane Res; 1980; 6():337-40. PubMed ID: 6992532 [No Abstract] [Full Text] [Related]
35. Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue. Huddleston CB; Hammon JW; Wareing TH; Lupinetti FM; Clanton JA; Collins JC; Bender HW J Thorac Cardiovasc Surg; 1985 Feb; 89(2):190-5. PubMed ID: 2578591 [TBL] [Abstract][Full Text] [Related]
36. Platelet alterations in shear flow: dose response of prostacyclin on human platelets. Hung TC; Butter DB; Graham MF; Lewis JH; Zhao JQ; Haubold AD Trans Am Soc Artif Intern Organs; 1983; 29():436-41. PubMed ID: 6424310 [No Abstract] [Full Text] [Related]
37. Synthesis of a highly potent analogue of prostacyclin, (-)-5-methyleneisocarbacyclin. Amemiya S; Koyama K; Saito S; Kojima K Chem Pharm Bull (Tokyo); 1986 Oct; 34(10):4403-5. PubMed ID: 3549013 [No Abstract] [Full Text] [Related]
38. 10,10-Difluoro-13-dehydroprostacyclin: a chemically and metabolically stabilized potent prostacyclin. Fried J; Mitra DK; Nagarajan M; Mehrotra MM J Med Chem; 1980 Mar; 23(3):234-7. PubMed ID: 6988588 [No Abstract] [Full Text] [Related]
39. Effects of prostacyclin, 6-keto-PGF1 alpha PGF2 alpha and 15[S]15-methyl-PGF2 alpha on platelet aggregation in vitro. Marmo E; Somma A; Ottavo R; Vairo G; Spaziante G; DiMezza F; Paone G J Med; 1981; 12(2-3):97-108. PubMed ID: 7024451 [No Abstract] [Full Text] [Related]
40. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry. Eggerman TL; Harker LA; Andersen NH; Wilson CH Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]